Healthcare Industry News: Janssen Pharmaceuticals
News Release - June 18, 2010
Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc.WOODCLIFF LAKE, N.J.--(HSMN NewsFeed)--Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announces the appointment of Lonnel Coats to the position of President and Chief Executive Officer of Eisai Inc. Previously, Mr. Coats held the position of President and Chief Operating Officer. In addition, Mr. Coats has been appointed Senior Vice President of the Pharmaceuticals Business in the United States at Eisai Co. Ltd., where he will have additional responsibility for leading Eisaiís Global Medical and Marketing division.
In his elevated role, Mr. Coats will be responsible for the strategic direction of the U.S. business. He will provide administrative oversight to all operating companies in the U.S. including Morphotek, Inc. and Eisai Machinery U.S.A., and will report directly to Mr. Haruo Naito, President and Chief Executive Officer of Eisai Co., Ltd. in Japan. Mr. Coats succeeds Mr. Hajime Shimizu, who has been appointed President of New Markets at Eisai Co., Ltd.
Mr. Coats joined Eisai Inc. as a regional sales director in 1996 when the company was first establishing its sales force and planning for the launch of its first pharmaceutical product in the U.S. Since then, he has rapidly advanced within the company in roles of increasing responsibility. In 2001, Mr. Coats served as Vice President of Human Resources, leading the organization to establish Eisai Inc.ís five-year vision and corporate values. In 2003, he was appointed Vice President of U.S. Sales and Marketing and in 2004, he assumed the position of President and Chief Operating Officer of Eisai Inc.
Mr. Coats serves on the Board of Trustees at the University of Sciences in Philadelphia and is Eisaiís representative on the Health Section Governing Board at the Biotechnology Industry Organization. In 2008, he served as board vice chairman and an executive committee member of the National Pharmaceutical Council.
Mr. Coats holds a B.S. in Public Administration from Oakland University in Michigan. He began his career in sales at Pepsi-Cola, where he was hired as a management trainee upon completion of the companyís Minority Scholar Program. In 1988, he joined Janssen Pharmaceuticals Inc., a division of Johnson and Johnson, as a sales representative where he held various positions within sales management during his eight-year tenure.
Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2009 (year ended March 31, 2010) sales of approximately $3.9 billion. Eisaiís areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The companyís areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.
Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. Eisai employs approximately 11,000 employees worldwide.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.